Not yet available, we are working hard on this format.
View the pre-filled pensOrigin
A tanning peptide that did something else
PT-141 descends from melanotan II, which was being studied for pigmentation. During that work an unrelated effect on arousal was observed, and a separate development programme grew out of it.
That origin explains the family resemblance: both act at melanocortin receptors. The two compounds differ in which receptors they engage and how strongly, which is why one is associated with pigmentation and the other is not.
Melanocortin receptors are numbered one to five and are distributed very differently: some in skin, some in the brain, some in immune tissue. Which subtypes a compound engages, and how firmly, distinguishes two molecules from the same family far more than any difference in their sequences does. The receptor literature indexed on PubMed is organised around exactly that distinction.
Mechanism
Central, not vascular
The better-known erectile dysfunction drugs are PDE5 inhibitors: they act on blood flow, downstream of arousal. PT-141 acts at melanocortin receptors in the central nervous system, which puts it upstream, on the signal rather than the plumbing.
That difference is the reason the compound was pursued at all. A mechanism that operates on desire rather than on vasculature addresses a different problem, and it is the basis of its approved indication in women.
The question behind most searches for what is pt-141 is whether a central mechanism outperforms a vascular one. There is no general answer available, because the two act at different points in the same sequence of events, and the trials registered under the bremelanotide name are where the evidence for the central route was gathered in the first place.
At a glance
| Also known as | Bremelanotide |
| Derived from | Melanotan II research |
| Target | Melanocortin receptors, central nervous system |
| Contrast with | PDE5 inhibitors, which act on blood flow |
| Approved as | Vyleesi, for HSDD in premenopausal women |
| Format | Nasal spray, with oxytocin |
| Purity | ≥ 99% (HPLC) |
| Category | Research use only |
Material specification. It stops where the effect questions begin.
In practice
Why it is paired with oxytocin here
This catalogue supplies PT-141 in a nasal spray alongside oxytocin. Both are studied in the context of social and intimate behaviour, and oxytocin acts through an entirely separate receptor system.
A combination product is a convenience for research protocols that call for both, not a claim that the two are synergistic. We are not aware of controlled work establishing that they are.
The oxytocin file covers that second component and why its receptor system is genuinely separate rather than adjacent. The kisspeptin page covers the third compound in this area, which acts further upstream again, at the level of the hormonal cascade rather than the behavioural signal.
Format
Why PT-141 is supplied as a nasal preparation
A spray is not a softer version of an injection, and the reason this compound appears in that format is not convenience. Melanocortin work has a long history of using mucosal delivery, and a preparation built for the nasal route raises its own questions about concentration, delivered volume and consistency between actuations that a pre-filled pen simply does not have to answer.
The comparison between the two routes sets out what changes and what stays put. What stays put is the material itself: the same peptide, the same certificate, the same specification, with the route governing how much of it reaches anything rather than what the compound is.
What we supply
PT-141 in the catalogue
Laboratory-released at 99% or better, one certificate per lot.
Related reading
Where PT-141 fits in
Further material for readers who want depth.
Frequently asked
About PT-141
Questions we answer often enough to publish.